Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Semin Arthritis Rheum. 2015 Jun 19;45(3):309–314. doi: 10.1016/j.semarthrit.2015.06.011

Table 2.

Unadjusted and Adjusted Hazard Ratios (95% Confidence Intervals) for Mortality (N=162)

Risk Factor Unadjusted HR
(95% CI)		 Adjusted HR
(95% CI)
AC + vs. − 1.36
(0.67, 2.76)		 1.53
(0.68, 3.44)		 -
NUC + vs. − 0.71
(0.32,1.61)		 0.62
(0.25, 1.54)		 -
Scl-70 + vs. − 1.85
(0.56, 6.12)		 1.27
(0.29, 5.52)		 -
Other + vs. − 1.16
(0.44, 3.06)		 1.40
(0.52, 3.76)		 -
RNA pol + vs. − NA* -
U1RNP +vs. − 0.98
(0.23, 4.12)		 1.41
(0.29, 6.88)		 -
Negative + vs. − 0.38
(0.06, 3.03)		 - - - - - 0.44
(0.06, 3.28)
Age, y 1.02
(0.98, 1.05)		 1.03
(0.99, 1.08)		 1.03
(0.99, 1.07)		 1.04
(0.99, 1.08)		 1.03
(0.99, 1.08)		 1.04
(1.00, 1.08)		 1.04
(1.00, 1.08)
Sex, male vs.
 female		 1.92
(0.72, 5.08)		 1.79
(0.58, 5.49)		 1.69
(0.56, 5.05)		 1.61
(0.54, 4.81)		 1.55
(0.52, 4.61)		 1.48
(0.47, 4.59)		 1.52
(0.51, 4.51)
Race, non-white
 vs. white		 1.46
(0.65, 3.27)		 1.59
(0.64, 3.95)		 1.77
(0.70, 4.49)		 1.64
(0.66, 4.10)		 1.64
(0.65, 4.10)		 1.67
(0.67, 4.21)		 1.52
(0.61, 3.82)
SSc disease
 duration, y		 1.00
(0.96, 1.03)		 0.99
(0.95, 1.03)		 0.99
(0.96, 1.03)		 1.00
(0.96, 1.04)		 1.00
(0.96, 1.04)		 1.00
(0.96, 1.03)		 1.00
(0.61, 1.03)

AC=anticentromere, NUC=nucleolar ANA, Scl-70=anti-topoisomerase I, Other=other non-specific positive ANAs, overlapping antibodies, RNA pol=RNA polymerase III.

*

No PHAROS patients with +RNA pol died during the follow-up period.